0001610717-23-000258.txt : 20230906 0001610717-23-000258.hdr.sgml : 20230906 20230906183709 ACCESSION NUMBER: 0001610717-23-000258 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230901 FILED AS OF DATE: 20230906 DATE AS OF CHANGE: 20230906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Throne Jason CENTRAL INDEX KEY: 0001790865 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38915 FILM NUMBER: 231240568 MAIL ADDRESS: STREET 1: C/O IDEAYA BIOSCIENCES, INC. STREET 2: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc. CENTRAL INDEX KEY: 0001676725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474268251 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-6209 MAIL ADDRESS: STREET 1: 7000 SHORELINE COURT, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Ideaya Biosciences, Inc. DATE OF NAME CHANGE: 20160609 4 1 form4.xml X0508 4 2023-09-01 0001676725 IDEAYA Biosciences, Inc. IDYA 0001790865 Throne Jason C/O IDEAYA BIOSCIENCES, INC. 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO CA 94080 true Chief Legal Officer true Common Stock 2023-09-01 4 M 0 2100 12.86 A 2100 D Common Stock 2023-09-01 4 S 0 2100 30.0298 D 0 D Common Stock 2023-09-05 4 M 0 1737 12.86 A 1737 D Common Stock 2023-09-05 4 S 0 1737 30.0287 D 0 D Stock Option (Right to Buy) 12.86 2023-09-01 4 M 0 2100 0 D 2032-02-29 Common Stock 2100 56650 D Stock Option (Right to Buy) 12.86 2023-09-05 4 M 0 1737 0 D 2032-02-29 Common Stock 1737 54913 D The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023. This transaction was executed in multiple trades in prices ranging from $30.00 to $30.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $30.00 to $30.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Jason Throne 2023-09-06